A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis
A study for patients with AL amyloidosis using study drug NEOD001
Sponsor: Prothena Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAP5356
U.S. Govt. ID: NCT02312206
Contact: Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected by amyloid deposits.
This study is closed
Suzanne Lentzsch, MD
Do You Qualify?
Have you been newly diagnosed with AL amyloidosis and have not yet received treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton